What INmune Bio Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 3 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 31,026 |
| Disposed | 0 | 0 |
| Net activity | +0 | +31,026 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Lowdell Mark William | Chief Scientific Officer | Jul 02 | Exercise / conversion · M | +7,211 | $1.40 | +$10.1K | 1,518,017 |
| Juda Scott | Director | Jul 02 | Exercise / conversion · M | +14,801 | $1.40 | +$20.7K | 86,404 |
| Moss David J | Chief Executive Officer | Jul 02 | Exercise / conversion · M | +9,014 | $1.40 | +$12.6K | 1,294,883 |
| Moss David J | Chief Financial Officer | Sep 30 | Open-market buy · P | +10,000 | $5.29 | +$52.9K | 1,285,869 |
| Tesi Raymond Joseph | President and CEO | Sep 12 | Open-market buy · P | +15,380 | $6.38 | +$98K | 1,554,106 |
| Moss David J | Chief Financial Officer | Sep 12 | Open-market buy · P | +7,690 | $6.38 | +$49K | 1,275,869 |
| Juda Scott | Director | Jun 25 | Open-market buy · P | +5,000 | $7.27 | +$36.4K | 71,603 |
| Juda Scott | Director | Apr 19 | Open-market buy · P | +29,603 | $8.32 | +$246K | 66,603 |
| Lowdell Mark William | Chief Scientific Officer | Apr 19 | Open-market buy · P | +14,423 | $8.32 | +$120K | 1,510,806 |
| Tesi Raymond Joseph | President and CEO | Apr 19 | Open-market buy · P | +18,028 | $8.32 | +$150K | 1,538,726 |
| Moss David J | CFO, Treasurer & Secretary | Apr 19 | Open-market buy · P | +18,028 | $8.32 | +$150K | 1,268,179 |
| Juda Scott | Director | Nov 10 | Open-market buy · P | +7,000 | $6.95 | +$48.7K | 37,000 |
| Schroeder Timothy j | Director | Jul 12 | Disclosed 10b5-1 sale · S | −10,000 | $11.01 | −$110K | 82,187 |
| Moss David J | CFO, Treasurer & Secretary | Mar 17 | Open-market buy · P | +2,500 | $6.43 | +$16.1K | 1,250,151 |
| Moss David J | CFO, Treasurer & Secretary | May 27 | Open-market buy · P | +3,000 | $6.79 | +$20.4K | 1,247,651 |
| Tesi Raymond Joseph | President and CEO | May 26 | Open-market buy · P | +6,300 | $6.41 | +$40.4K | 1,520,698 |
| Moss David J | CFO, Treasurer & Secretary | May 26 | Open-market buy · P | +7,700 | $6.27 | +$48.3K | 1,244,651 |
| Ganjei James Kelly | Director | Mar 22 | Grant / award · A | +17,793 | $8.43 | +$150K | 17,793 |
| Tesi Raymond Joseph | President and CEO | Mar 22 | Grant / award · A | +23,724 | $8.43 | +$200K | 1,514,398 |
| Lowdell Mark William | Chief Scientific Officer | Mar 22 | Grant / award · A | +23,590 | $8.43 | +$199K | 1,496,383 |
Loading...